[Management of atrial fibrillation in 2011].
Some new guidelines have been published by European (2010) and American (2011) Societies of Cardiology regarding to the management of atrial fibrillation, the most frequent arrhythmia affecting from 1 to 2% of the global population. In this article we summarize and analyse the new aspects of these guidelines in which the different types of atrial fibrillation are redefined, as well as new criterias for the indication of oral anticoagulation and bleeding risk. New antiarrhythmic and anticoagulant molecules also appear in these guidelines, and there is growing evidence for the use of catheter ablation.
Département de Cardiologie, C.H.U. Brugmann, Bruxelles. emmanuel.catez@chu-brugmann.be
E
E
Catez
B
B
Sina
P
P
De Coodt
B
B
Peperstraete
E Tran
ET
Ngoc
J
J
Castro
M
M
Morissens
G
G
Flores
M
M
Strachinaru
T
T
Verbeet
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000503:physiopathology / Q000628:therapy*; D017115:Catheter Ablation; D004554:Electric Countershock; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents